Skip to main navigation Skip to search Skip to main content

The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study

  • Yen Hsiang Huang
  • , Jen Yu Hung
  • , How Wen Ko
  • , Po Lan Su
  • , Chun Liang Lai
  • , Huang Chih Chang
  • , Te Chun Hsia
  • , Sheng Hao Lin
  • , Kuan Li Wu
  • , Cheng Ta Yang
  • , Wu Chou Su
  • , Yi Chun Chu
  • , Chin Chou Wang
  • , Wei Yu Liao
  • , Yen Ting Lin
  • , Ching Hsiung Lin
  • , Meng Chih Lin
  • , Kuo Hsuan Hsu
  • , Jeng Sen Tseng
  • , Tsung Ying Yang
  • Kun Chieh Chen, Mei Hsuan Lee, Sung Liang Yu, Chao Chi Ho, Gee Chen Chang*
*Corresponding author for this work
  • Veterans General Hospital-Taichung Taiwan
  • Kaohsiung Medical University
  • Chang Gung Memorial Hospital
  • National Cheng Kung University
  • Buddhist Dalin Tzu Chi Hospital
  • Chang Gung University
  • China Medical University Taichung
  • Changhua Christian Hospital
  • National Taiwan University
  • Chung Shan Medical University
  • National Yang Ming Chiao Tung University

Research output: Contribution to journal › Journal Article › peer-review

5 Scopus citations

Abstract

Background: The relative importance of predictive factors for advanced non-small cell lung cancer (NSCLC) patients on epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment remains unclear. Materials and methods: We retrospectively enrolled advanced NSCLC patients with single first-generation EGFR-TKI treatment for ⩾5 years (Y) in Taiwan. Clinical data was collected and compared with those of another cohort with single first-line EGFR-TKI treatment for <5 Y. Plasma cell-free DNA (cfDNA) samples were collected from patient subsets, pre- and post-TKI, in the >5 Y group. Results: Overall, 128 and 278 patients were enrolled in the ⩾5 Y and <5 Y groups, respectively. Significant factors in the multivariate analysis of patients’ characteristics including Eastern Cooperative Oncology Group performance status 0–1, postoperative recurrence, without brain metastasis, oligometastasis (each score of 2), female sex, erlotinib use, and without bone metastasis (each score of 1), were incorporated into a risk scoring system. The area under the receiver operating characteristic curve was 0.82 [95% confidence interval (CI): 0.78–0.86]. Of the plasma cfDNA samples from 33 patients in the ⩾5 Y group, only 1 had a T790M in 25 patients without progressive disease. In 27 patients with single agent use for ⩾96 months, 22 (81.5%) received local treatment (surgery or radiotherapy) for the primary lung tumor before and during TKI treatment. Conclusion: For NSCLC patients with single first-generation EGFR-TKI use for ⩾5 Y, factors with different relative importance exist and the risk-scoring model is feasible with modest accuracy. The role of local treatment for primary tumors in patients with long-term TKI use requires further investigation.

Original languageEnglish
JournalTherapeutic Advances in Medical Oncology
Volume13
DOIs
StatePublished - 2021

Bibliographical note

Publisher Copyright:
© The Author(s), 2021.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • epidermal growth factor receptor
  • local treatment
  • more than five years
  • non-small cell lung cancer
  • scoring model
  • tyrosine kinase inhibitor

Fingerprint

Dive into the research topics of 'The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study'. Together they form a unique fingerprint.

Cite this